Articles tagged with Personalized Medicine
Researchers have identified two bacterial species that promote intestinal inflammation in IBD patients, and developed a method to selectively target them. The study found that targeting these bacteria with specific compounds may provide a more effective and safer treatment option for IBD patients.
New research in nuclear medicine and molecular imaging has led to breakthroughs in cancer diagnosis and treatment. Multispectral optoacoustic tomography detects blood flow problems before reconstructive surgery, while FAPI PET imaging assesses liver fibrosis in people with metabolic dysfunction–associated steatotic liver disease.
A hybrid approach of intraarterial and intravenous peptide receptor radionuclide therapy (PRRT) delivers three times more radiation to liver metastases, resulting in 67% partial response rate at three months and 87% at six months. The treatment enhances tumor control without added major toxicity.
Scientists identify chimeric RNA molecules as essential in cellular health and disease, finding they play a wide variety of critical roles in vital cellular processes. Faulty chimeric RNA are often malfunctioning in breast cancer tumors, prompting new cancer treatments targeting specific chimeras.
A new study published in Science Translational Medicine found that nearly 100,000 people carried genetic variants that affect medication responses. The study highlights the value of genetic testing for certain medications and suggests that electronic health record alerts could help clinicians make informed prescribing decisions.
Researchers developed AI tools to simplify medical reports and improve doctor-patient communication, addressing a widespread issue affecting patient health management. The study evaluates four language model families and finds that Llama-3.2-3B and RigoChat-v2-7B excel in efficiency and readability, respectively.
Jennifer Frederick, an oncology clinical trial organizer at Wash U Medicine, received the 2026 Alliance Clinical Research Professionals Research Integrity Service Award for her dedication to helping cancer patients access clinical trials. Her work ensures that trials run smoothly and safely, with a focus on patient advocacy and compass...
Research in PSMA radioligand distribution reveals increased radiation exposure to healthy tissues. A new PET tracer detects kidney fibrosis, while EGFR-targeted radiotheranostics show promise against liver cancer. Clinical trials evaluate CXCR4-targeted therapy for acute leukemia and patient guidance for PSMA therapy.
A team of engineers and surgeons from Johns Hopkins Medicine has developed a temporary implant that can monitor spinal cord injuries, providing real-time feedback to medical teams. The device, called Multimodal Ultrasound System for Injury Care (MUSIC), can track changes in blood flow and identify potential complications, aiming to imp...
Exerkines, exercise-responsive signals, coordinate interorgan crosstalk to regulate glucose and lipid metabolism, insulin sensitivity, and inflammation. Exerkine-based diagnostics and therapeutics hold promise for precision management of chronic metabolic diseases.
A groundbreaking clinical case demonstrates precise liver-targeted base editing with no detectable off-target alterations. The therapy effectively converts the patient's homozygous genotype to a heterozygous state, holding immense therapeutic potential for hereditary liver disorders.
Researchers have made significant advancements in nuclear medicine, improving treatment outcomes for prostate cancer, detecting cancer recurrence, and predicting treatment outcomes. Studies have shown that combining imaging methods, such as PET/CT and MRI, can improve detection of prostate cancer, while diagnostic scans may predict tum...
A new study led by UC Davis researchers finds that narrower surgical margins than previously thought can achieve cancer control in pediatric patients with non-rhabdomyosarcoma soft tissue sarcomas. The study, which evaluated 266 patients, found that close surgical margins as little as a millimeter can preserve precious healthy tissue a...
A phase 1 trial of the alpha radiopharmaceutical therapy Pb-ADVC001 showed well-tolerated doses and encouraging signs of antitumor activity in patients with advanced prostate cancer. The therapy's optimized dose schedule and 100% overall response rate suggest potential for improved patient outcomes.
Researchers evaluated PET imaging with radiolabeled trastuzumab deruxtecan and targeted alpha therapy against HER2-positive cancer cells, revealing promising results in tracking therapy accumulation and suppressing tumor growth. PET imaging also linked metabolic patterns to pancreatic tumor outcomes and identified potential distant met...
Researchers propose targeting G protein-coupled receptors to slow aging, exploring AI, systems biology, and digital twins for therapy design. The approach could work alongside senolytic, metabolic, and regenerative strategies.
The therapy showed consistent efficacy and a manageable safety profile, with outcomes similar to those in the VISION trial. The findings support the use of PSMA-targeted radiopharmaceutical therapy in routine care for patients with mCRPC, including those eligible for retreatment.
Researchers propose novel therapies to rebalance GPCR signaling, potentially extending healthy years of life and delaying multiple age-related diseases. This network-level approach could give rise to personalized treatments and complement emerging longevity strategies.
Researchers at the University of East Anglia found that tiny changes in pupil size and blinking patterns can reveal an individual's mental workload during virtual reality tasks. This could lead to wearable systems that automatically adapt therapy in real-time, offering personalized pain relief for millions living with chronic pain.
Researchers have identified new predictors of relapse in children with acute lymphoblastic leukemia treated with immunotherapy drug blinatumomab, allowing for more precise treatment tailoring. The study also found genetic subtypes associated with poorer response to treatment and higher risk of relapse.
A new review examines how gut microbiota and metabolites reshape liver immunity and propose strategies to overcome immunotherapy resistance. The review discusses four major directions of gut microbiota intervention, including probiotics, fecal microbiota transplantation, engineered bacteria, and metabolite-based interventions.
A novel blood test detects lingering lung cancer traces in the bloodstream, predicting relapse risk and guiding timely personalized treatment. The test, known as liquid biopsy, tracks circulating tumor DNA and identifies patients at high risk of recurrence.
A Johns Hopkins Medicine-led team will build an artificial intelligence model to identify protein misfolding for earlier disease detection and treatment. The goal is to generate tools and resources for clinicians and researchers to diagnose and intervene at earlier stages of neurodegenerative conditions.
A new UVA study finds that Black children are more likely to develop severe asthma due to harmful inflammation, regardless of environmental factors. The research suggests tailored treatments for Black children with severe symptoms, and testing for high levels of T2 inflammation in all children with difficult-to-treat asthma.
Recent studies published in The Journal of Nuclear Medicine investigate novel radiohybrid ligands for prostate cancer therapy, AI models predicting prostate cancer survival, and PET tracers for meningioma treatment. These advancements show promise for personalized medicine and improved patient outcomes.
Researchers Dr. Hutan Ashrafian and Dr. Ahmad Guni discuss the expanding capabilities of medical AI, including predictive and preventive applications, and the need for technical and health-system advances to improve health outcomes. They will explore the safeguards needed for responsible and equitable adoption of increasingly capable A...
Early assessment with 68Ga-HER2 PET/CT during neoadjuvant therapy can predict pathologic complete response in patients with HER2-positive breast cancer, with a 85% success rate for those with tumor uptake decrease of at least 61%. This finding has implications for timely consideration of alternative treatment strategies or surgery.
Researchers propose recognizing recompensation as a distinct treatment-related disease state, distinguishing stable and unstable recovery, to better capture recovery and continuing risks after cirrhosis treatment. This framework could support more consistent research, clinical assessment, and long-term surveillance for patients recover...
Artificial intelligence can match human doctors in certain tasks, but human doctors are essential for making complex decisions about patient care. AI may identify a patient's medical condition, but human doctors must consider individual circumstances and make choices that work in the patient's best interest.
Juvmo, a Parkinson's disease drug, has been approved by the FDA and offers a new treatment option for patients, potentially reducing side effects. The drug's unique mechanism of action provides relief from motor symptoms, and its approval marks a significant milestone in the research of UVA Health scientists.
A new framework proposes evidence sufficiency, selective prediction, and deferral pathways for multimodal AI in cardiovascular medicine. Missing data are not noise, but rather informative about patient state, clinician decisions, and health system access.
Researchers developed new imaging approaches and tracers to target prostate cancer, breast cancer, and other conditions. These methods showed promising results in improving detection and treatment outcomes.
A new Cochrane review finds that pharmaceutical company marketing, including payments, gifts, and free meals, leads to less appropriate prescribing habits and higher medicine costs. The review analyzed millions of prescribers and found a clear dose-response relationship between paid-for meals and inappropriate prescriptions.
Researchers propose matching sensing frequency to biomarker type and pairing with contextual data like blink patterns and tear flow to separate true biological change from normal fluctuations. The goal is to design sensors that can trust readings over time, moving beyond just counting biomarkers.
The Journal of Nuclear Medicine publishes a comprehensive supplement on theranostics, covering radionuclide production, personalized dosimetry, and phase 3 trials. Academic nuclear medicine must keep pace with industry funding and evidence-based practices to train specialists and meet demand.
A study by the University of Osaka has identified shared disease mechanisms in lymphatic malformations, including the PI3K/AKT/mTOR pathway, and found that sirolimus, a drug targeting this pathway, is clinically effective across patients. The research also uncovered 10 additional disease-related molecules, including NFATC1, which may r...
The AFT-70 NAVIGATE trial tests a novel molecular residual disease-guided treatment strategy for ER-positive/HER2-negative breast cancer patients. The trial pairs giredestrant with longitudinal Signatera Genome MRD monitoring to identify patients who may benefit from treatment escalation with a CDK4/6 inhibitor.
Recent studies in The Journal of Nuclear Medicine have introduced new imaging techniques, including PET-based methods, to improve cancer diagnosis and treatment. Additionally, an open-source pipeline has been developed to automate tumor segmentation, and a new imaging approach has been shown to visualize therapeutic radionuclides.
The UVA Weber Symposium will discuss the latest research and advancements in metastasis, a complex area of cancer research and care. The event will bring together top scientists and physicians to present findings on cancer metastasis, genetics, and treatment considerations.
Recent studies published in The Journal of Nuclear Medicine have investigated new treatments for liver fibrosis, thyroid cancer, and prostate cancer, including the use of PET tracers and radioactive iodine therapy. These studies have shown promising results, including improved imaging and biochemical responses, and increased radiation ...
A novel autologous gene therapy for Wiskott-Aldrich syndrome has demonstrated durable clinical benefits in a phase 3 study, with 96% survival at 1 and 5 years. The treatment, etu-cel, has also reduced severe infections and moderate-to-severe bleeding events.
A new drug, Kamuvudine K-9, has been shown to preserve nerve fibers and halt neurological damage in a mouse model of multiple sclerosis. The drug, derived from HIV drugs, has been found to be more effective than existing treatments in restoring function and reducing inflammation.
A new, incisionless liver cancer treatment called histotripsy was associated with low rates of laboratory toxicity and procedural complications in a real-world review of 972 patients. However, the study found that 11% of patients died within 30 days, suggesting that advanced cancer and overall disease burden may be contributing factors.
The guideline establishes a framework for personalized phage therapy, including standardized procedures for selecting and testing phages, infrastructure development, and quality control. Clinical research indicates a favorable safety profile, but efficacy has yet to be fully demonstrated.
New research in nuclear medicine advances detection and treatment of clear cell renal cell carcinoma with high accuracy, while SSTR antagonists show potential for imaging and treatment of neuroendocrine tumors. Alternative beta-emitting radionuclides are also being explored for targeted radiopharmaceutical therapy.
The new guidelines, developed by leading experts, focus on improving sepsis care by strengthening systems for diagnosis, treatment, prevention, and quality improvement. Emerging technologies, such as next-generation diagnostics and artificial intelligence, are also being explored to enhance sepsis care.
A new AI tool has been developed to predict treatment and survival outcomes in patients with advanced non-small cell lung cancer treated with immunotherapy. The tool consistently outperformed standard clinical biomarkers, achieving high accuracy scores in predicting survival outcomes.
Researchers at CU Anschutz have developed CAR T-cell therapy to target two pathways that help colorectal tumors grow and evade the immune system, B7-H3 and IL-8. The therapy aims to provide a more durable response than traditional chemotherapy.
Several new nuclear medicine approaches are being developed and evaluated for their potential to improve cancer imaging and treatment. Researchers have made significant progress in targeting specific markers and molecules in cancer cells, including CD163, CEACAM5, and DLL3. These advancements offer promising avenues for developing more...
Research evaluated ITGA3 expression across breast cancer subtypes and found its significance in prognosis and therapeutic relevance. High ITGA3 expression was associated with shorter recurrence-free survival and poorer clinical outcomes, making it a potential prognostic biomarker and therapeutic target.
The American College of Cardiology and American Heart Association have introduced a new framework, Tactical Clinical Management (TCM), to evaluate cardiovascular risk and fitness for duty in tactical athletes. This guidance addresses the unique needs of professionals working in high-risk environments, where sudden incapacitation can af...
Researchers at the University of Münster have found that using biomarkers to identify high-risk patients can significantly reduce the risk of kidney damage after major surgery. The approach has great potential to help sepsis patients too, and the team is working to incorporate these findings into international guidelines for the treatm...
Researchers found that meal timing programs the liver's daily rhythms and can have serious metabolic and health consequences when out of sync. The liver uses food signals to activate metabolic pathways, which can conflict with the body's natural circadian clock, leading to health issues.
The authors propose a spectrum of clinical autonomy, ranging from advisory tools to navigator systems that work with minimal human oversight, to enable early prediction and prevention of disease. However, challenges related to clinical validation, integration, data quality, and regulatory approval limit widespread deployment.
Prostate cancer affects 1 in 8 men, with 60% diagnosed in men 65 and older. Clinical trials like Alliance's help improve early detection and treatment, reducing mortality rates by half since 1993. These trials also explore new treatments and survivorship strategies.
Researchers developed a dual-threshold approach for measuring tumor volume on PET/CT, showing higher total lesion volume associated with shorter overall survival and time to treatment failure. FAPI PET/CT improved detection of ovarian cancer spread, while CD8-targeted PET tracked immune response in lung cancer.
A new theranostic pair, 68Ga/177Lu-NYM096, shows excellent tumor uptake in clear cell renal cell carcinoma lesions and demonstrates early evidence of tumor response in patients. The radiotracer can identify tumors and deliver targeted radiotherapy, mitigating toxicity issues common with treatment.
UCSF's new center aims to train 1,000 health care providers annually and develop screening tools to identify eating disorders. The center will also serve as a national hub for eating disorders research, connecting investigators across institutions and disciplines.
USC researchers have developed custom, 3D-printed MRI sensors that provide clearer images of small organs in infants and children. The sensors, which can be customized to individual patients, are made in under 10 minutes and cost around $30.
A new research tool, PGS-TRI, analyzes family data to understand how genetics and environment contribute to autism risk. The tool provides a more precise look at how 'nature' and 'nurture' interact within families, allowing researchers to better understand the complex factors that shape a child's health.